PFS: On study vs. last prior therapy
Patients at risk, n
125
60
33
22
12
4
40
14
9
5
2
1
Median PFS (months)
On study: 11.0
Last prior therapy: 4.6
PFS (%)
Time from start of idelalisib (months)